u/emil_agyeman

Correction: that was clearance time, not carrier time. The lane table separates them for exactly this reason.

Contemporaneous records do not drift; reconstructed ones do, and the drift is systematic rather than random because memory smooths.

Took a baseline the week before starting purely because this board told me to.

vito_chowdhury is right that a reference interval is not a target. It is a description of a population.

Correction: that marker is reported in different units by different labs, which explains the tenfold difference you are seeing.

Did anything else change in that window — training, intake, hydration?

a single fasting insulin outside range is a reason to repeat, not to panic

Related substances itemised individually is a much stronger document than a single total, because it tells you the shape of the impurity profile rather than its size.

Attribution requires that one thing change at a time. A log with dose, training and intake all moving in the same fortnight cannot assign anything to any of them.

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

Was completely wrong about the gastric emptying story in a thread here two years ago. Someone corrected me with a citation and I have not made that mistake since.

write the concentration in the log too

That is a waist figure in the weight column. Easy mistake and it makes the chart look dramatic.

the value of a log is in month six, not week one

Disagree with reading anything into that. One value, one morning, and you changed two other things in the same window.

Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.

Which phase 2 arm are you quoting, and at what week?

Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.

Sent a vial to VendorInvestigate because there was almost nothing on file for this compound. 97.6% against a claimed 97.5%, and I posted it because the log needs entries.

That result is preclinical. Worth flagging, since the thread has been reading it as human data.

The half-life explanation was the thing that made weekly dosing intuitive for me rather than arbitrary.

Different laboratories use different assay platforms with different calibration. Comparing across labs adds a systematic offset that is invisible on the report.

the log is cumulative, that is the whole value of it

Added a sleep column late and immediately understood two of my worst weeks.

the co-agonism argument is about complementary mechanisms

That is a waist figure in the weight column. Easy mistake and it makes the chart look dramatic.

Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.

That is the 68-week readout, not the 72-week one. Different trial, different duration.

Tested three lots over a year rather than three vials from one lot. Cost the same and told me something completely different.

a lot of the confident posting here is extrapolation

baseline before you start is worth more than any later panel

What are you actually recording each week?

Is that the 48-week figure or an earlier readout?

Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all different.

phase 2 data only, and people quote it like it is a label

hugo_pires is right about the escalation being the variable. It explains most of the difficult reports here.

Is that the 48-week figure or an earlier readout?

Spent four months confusing area% and mass% in every post I made here. One explainer thread and it clicked permanently.

Agreed that consistent conditions matter more than frequency. Daily weights under varying conditions are noise.